suggesting a possible trend slowdown as has already occurred elsewhere [6, 7] . Since 2002, DRG 127 has been second in the ranking of the top 10 DRGs by number of admissions; yearly admissions corresponding to DRG 127 amounted to 0.3% of the Italian population [8] and 2.6% of all hospitalizations of acute patients in regular wards [5] .
The financial burden of HF is high. Direct medical costs (of which two-thirds are due to hospitalizations) are 1-2% of the overall health expenditure in developed countries [9] . In the USA, the estimated hospitalization costs in 2008 amounted to $18.8 billion, corresponding to 0.9% of the overall health expenditure [1] . With regard to Italy in 2008, the tariff of DRG 127 was multiplied by the respective number of hospitalizations, and a cost value was obtained (€618 million), corresponding to 1.2% of the total hospital public expenditure [5, 8] . The tariff chosen for this estimate was the mean value of the regional DRG tariffs in Italy, weighted with the corresponding number of admissions [10] .
In the management of AHF, an ideal strategy is to increase myocardial contractility without increasing oxygen consumption due to increased aortic pressure. This dual goal is pursued by inodilators, a class of drugs that increase contractility and cause vasodilatation [11] .
Inodilators are the first-choice class of drugs for the treatment of AHF. Levosimendan is a relatively recent inodilatory agent combining positive inotropic and vasodilating actions through its calcium-sensitizing and potassiumchannel opening effects. The mechanism for such an accomplishment is novel [12, 13] .
A number of studies have been published on the safety and efficacy of levosimendan, a d m i n i s t e r e d a s i n i t i a l t r e a t m e n t t o hospitalized patients. Indeed, the body of evidence is one of the largest ever produced regarding a new agent for the treatment
INTRODUCTION
Among cardiovascular diseases, heart failure (HF) is sometimes referred to as a "final stage" condition. The prognosis is poor, with a mortality rate of approximately 50% within the first 5 years following diagnosis [1] . HF is a complex clinical syndrome that can result from any structural or functional cardiac or noncardiac disorder, which leaves the heart unable to pump blood to match the bodies requirements. Acute HF (AHF) may be either de novo HF or worsening (decompensation) of chronic HF, both requiring urgent care [2] .
T h e i n c i d e n c e a n d p r e v a l e n c e o f HF increases with age, affecting more women than men (higher incidence in women may be due to men dying earlier, typically from myocardial infarction). Therefore, with the ongoing aging of the population, the disease is more and more widespread, notably in the industrialized world [3] . In the USA in 2006, the prevalence of HF in the general population was approximately 2%, with hospitalizations amounting to 1.1 million (0.4%) [1] .
Due to a lack of more specific data, the number of hospitalizations can be taken as an order of magnitude of the incidence of HF in 
METHODS

The Reference Study
The present analysis uses Italian clinical data.
It is based on a retrospective study conducted on patients with AHF who had been admitted to a major teaching hospital located in Rome [14] . The main studies are summarized in chronological order in Table 1 [15] [16] [17] [18] [19] [20] .
In a recent literature review of intravenous levosimendan, all 45 randomized clinical trials published on levosimendan and reporting mortality data were selected (which included 5,480 patients), and an in-depth meta-analysis was performed (the most comprehensive and statistically robust to date) [14] . The most frequent comparators were dobutamine or placebo, and other comparators were other inodilators (milrinone, enoximone), prostaglandin E1, or no comparator. The findings showed, both overall and in different subgroups, survival gains in patients receiving levosimendan and a reduction in length of stay (LOS) in patients treated for AHF.
Despite these gains, when compared with dobutamine, levosimendan is perceived as an expensive alternative. The objective of the and the readmission rate at 12 months (7.6% vs.
14.3%; P < 0.05; rate reduction: 6.7%).
The Economic Analysis
The present evaluation was conducted as a cost analysis (though not as a cost-minimization analysis, since efficacy is not equal between the competing treatments considered here). In this approach, the comparative costs and savings of alternative treatments were analyzed from the perspective of the payer [22] . This analysis did not take into account the above-mentioned benefits of levosimendan in improving symptoms and reducing mortality versus dobutamine. Instead, its approach allowed the payer to assess the economic impact of levosimendan treatment and to make a rational choice among alternatives. 
Savings from LOS Reduction
A DRG tariff is constant (up to a point), and a hospital is paid even when variable costs for the patient's care cease following discharge.
Such "undue" coverage (arising when the patient is discharged in advance compared to a LOS taken as reference) corresponds to a gain for the hospital. This is not true with regard to fixed costs, such as overheads and medical staff, which are not linked to individual hospitalizations; in this case, the coverage of such costs by the DRG tariff is justified regardless of the actual LOS.
Ideally, savings in the variable costs due to LOS reduction should be measured on the basis of the average variable cost per day of a patients stay (including drugs, subsidiaries, diagnostic tests and procedures, and hotel costs), with reference to a cardiology department. However, as these types of specific data are generally unavailable in Italy (or ad-hoc research would be required), they were evaluated in the present study using the above-mentioned gain as a proxy. For the sake of precision, it should be pointed out that an average value would overestimate the correct value, due to the right-skewed distribution of the variable cost as a function of the in-patient stay time [22] . However, a precise estimate could not be attained in the present study.
Savings from a Reduction in Rehospitalization Rate
As far as a full occupancy assumption can is generally only a subset of the whole activity of the department, which has a mix of DRGs.
Therefore, a rate reduction of 10% does not mean 10 beds are left free; fewer beds will be free because that rate does not refer to the 100 beds of the whole department, but only to the subset with DRG 127. The number of beds actually released will ultimately depend on the proportion of the number of admissions for AHF divided by the total number of admissions included in the mix of the department.
The Model
The present analysis was of an incremental type, confronting the cost difference between the two in-hospital therapies (levosimendan and dobutamine, respectively) with the analogous savings difference. Costs and savings are referred to one patient/treatment case. The outcome of the analysis can then be defined as:
The definitions in the model are: net savings (NS); savings from using levosimendan (S L );
savings from using dobutamine (S D ); cost for using levosimendan (C L ); cost for using dobutamine (C D ).
Costs
With regard to treatment costs, in the present study the DRG 127 tariff is considered as a proxy of the costs borne by a hospital for the hospitalization of one patient with AHF. As such,
we have:
The 
Savings from LOS Reduction
The savings corresponding to each discharge occurring in advance due to levosimendan are evaluated in two steps. First, a nominal "daily" DRG tariff is calculated by dividing the DRG 127 tariff by the average LOS. Second, the result is multiplied by the LOS reduction;
i.e., by the number of days for which the hospital is reimbursed after the patient has been discharged (1.5 days in the reference study [21] ). The definition used in the model is: savings from LOS reduction due to levosimendan (S LOS ).
As already pointed out, such additional revenue is not net revenue. Actually, only a quota should be taken into account corresponding to the variable costs, but this operation is hardly feasible as, as already stressed, variable costs in a hospital department are very difficult to estimate. Consequently, the savings are overestimated.
Savings from a Reduction in Rehospitalization Rate
Clearly, the additional revenue for each treatment with levosimendan (instead of dobutamine) is not the entire difference between the average tariff of the DRG mix in the cardiology department and the DRG 127 tariff.
It would only be so when any treatment with dobutamine was followed by a rehospitalization and any treatment with levosimendan was followed by no rehospitalization (i.e., if the reduced rehospitalization rate due to levosimendan was 100%). Instead, the amount will be proportional to the actual reduction assessed in the rehospitalization rate (6.7%
in the reference study [21] ). Such amount is defined in the model below (savings from rehospitalization rate reduction due to
Total savings: 
Unit Costs
The cost for one vial of levosimendan (€697) was taken from the reference study [21] .
Following devolution of healthcare management from a national to a regional base, variation can be found among the local tariffs of a given DRG. With regards to DRG 127, an average data for Italy (€3,079) was calculated on the 2008 regional tariff values [8] , weighted with the corresponding number of admissions [5] .
The national average LOS (9.1 days), which was used to estimate a nominal "daily" DRG tariff, was also drawn from the same source [5] . In particular, the average revenue per discharged patient (based on data in Table 2 ) was adopted as a proxy for the average tariff of the DRG mix in the cardiology department (€5,885).
Sensitivity Analysis
The impact of possible variations in the estimated inputs of the model was tested with a one-way deterministic analysis. With regard to the reduction of LOS due to levosimendan, the low and high values of its 95% confidence intervals (CI) were respectively assumed.
A similar approach was adopted for the reduction of the rehospitalization rate.
The nominal "daily" DRG 127 tariff overestimates the real savings from LOS reduction, because it includes a fixed-costs quota, ICU intensive care unit, LOS length of stay a The discrepancies within each setting between admitted and discharged patients are chiefly explained by considering that many patients who are admitted to the ICU are later transferred to the regular ward, from which they are eventually discharged. Other inter-hospital transfers, as well as stays extending from 1 year to the following year, can account for the residual explanation which cannot be considered additional revenue.
As the real amount of such quota could not easily be known, the value inputted in the base case model was halved, as an approximate adjustment, in the sensitivity analysis.
The impact of a full occupancy assumption on savings due to the reduction in rehospitalization rate was tested conjecturing that in the narrow interval of a 100% occupancy the attenuation of the assumption might imply that the 
RESULTS
Base Case
The incremental cost of the treatment with levosimendan (€697; i.e., the cost for one vial)
is in balance with the incremental treatment savings (€694) ( Table 3 ). This benefit is the sum of two addends: the major addend (€508) stems from the LOS reduction (1.5 days), the other addend (€186) from the reduction in rehospitalization rate (6.7%).
Sensitivity Analysis
The outcomes from the sensitivity analysis are reported by decreasing order of impact magnitude in Table 4 .
In Economic results appear to be most sensitive to LOS reduction (1.5 days). When such reduction was set at the highest value reasonably assumable (corresponding to the 95% CI higher limit), the treatment net benefit would increase to €470; whereas at the lowest value the loss would be as big, in absolute value. Of course, these values represent only the two extremes in the distribution of the likely net benefit values as a function of LOS reduction. CI confidence interval, DRG 127 diagnosis-related group code 127 (heart failure and shock), LOS length of stay
Relaxing the assumption of full occupancy in a cardiology department (i.e., considering an occupancy rate ≤98.5%), the net savings would be negative (-€189) .
DISCUSSION
The present cost analysis was performed in order to evaluate the economic impact of This analysis exploits the real hospitalization outcomes from an Italian retrospective study [21] .
As far as comparison is possible, such outcomes appear to be in line with those which are reported in published clinical trials of levosimendan [15] [16] [17] [18] [19] and in a comprehensive meta-analysis [14] , in particular with regards to shortened LOS; the gain of 1.5 days reported by Fedele et al. [21] is the same as that reported by Landoni et al. [14] . In other words, all these clinical findings appear to be confirmed by a "real-life" clinical experience in Italy.
A similar appraisal can be formulated about the consistency between the present analysis results and the conclusions of various economic evaluations of levosimendan [23] [24] [25] [26] . can generate biased results [27] . However, the consideration could be made that an expensive drug, like levosimendan, is given to the sicker patients, which would represent a "conservative" bias.
With regard to savings from LOS reduction, resulting data is to some degree overestimated since the calculation method which, for lack of specific information, had to be adopted bypasses the problem that the cost distribution is not A further benefit from the reduction in rehospitalization rate might be considered. One-tenth of such amount (i.e., €2,500) could then be assumed as a rough measure of the value of a 10% change in a subject's quality of life.
No elicitation was performed in the reference study [21] on health state utility values in AHF, so data from other sources, which shall be reported here, have a purely orientative value.
In a study conducted from 1977 to 1997 in the UK, 5,102 patients with newly diagnosed type 2 diabetes were recruited [30] . life. Moreover, it takes at least 1 year to make up for this loss [31] .
Also in this latter study, the limitations in comparability are strong; the quality of life of a patient with AHF is lower than the general populations, and the AHF condition is different from a myocardial infarction. But in light of the study, as a first approximation, avoiding a hospitalization due to AHF might reasonably be worth €2,500 (as this amount was assumed to correspond to a 10% change in quality of life, which is smaller than a 20% loss due to a cardiovascular event) [31] .
Following one treatment with levosimendan, rehospitalization is reduced by 6.7% (compared with dobutamine [21] ). In these terms, a €2,500 × 6.7% = €165 additional gain could be deemed to correspond to that treatment. Of course, such benefit would be outside the hospital's strictly economic perspective (for this reason, it has been discussed but not included in the core of the evaluation). On the other hand, it should not be completely neglected by a decision maker who, like a hospital manager, is committed to patients' health and their health-related quality of life.
In accordance with this kind of argument, the reduction in the mortality rate at 1 month as a result of the treatment with levosimendan (2.1% vs. 6.9% [21] ) should be appreciated too.
Considering that in 2010 approximately 200,000
hospitalizations occurred with DRG 127 [5] , almost 10,000 patients could be saved from death (at least at 1 month) every year. Notably, the survival benefits observed in the Italian study match those in the recent comprehensive meta-analysis [14] .
CONCLUSION
For all the limitations discussed in this analysis, levosimendan appears to be a competitive alternative to dobutamine for the treatment of AHF in an Italian hospital setting.
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